ADIAL PHARMACEUTICALS, INC. (ADIL): Nasdaq/NYSE listing notice — Adial Pharmaceuticals regains compliance with Nasdaq stockholders' equity minimum

ADIAL PHARMACEUTICALS, INC.

Regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5M stockholders' equity.
Nasdaq will monitor compliance; failure to show compliance in next periodic report could lead to delisting.
Company issued press release on November 29, 2023 announcing the compliance notice.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ADIAL PHARMACEUTICALS, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 29, 2023, Adial Pharmaceuticals, Inc. (the “Company”), received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that based on the Current Report on Form 8-K that the Company filed with the Securities and Exchange Commission on November 28, 2023 it determined that the Company was in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”). The letter further stated that if the Company fails to evidence compliance with the Rule upon filing its next periodic report it may be subject to delisting. At that time, Nasdaq staff will provide written noti

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-091094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.